Navigation Links
NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
Date:10/30/2009

EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.

"This model tests both the penetration of the nail as well as the effectiveness of the compounds against the targeted fungus. What is remarkable is that, after treatment, the Aganocide formulations were able to eradicate the fungi grown on the other side of the nail, hence indicating not only good penetration but a good antifungal activity against T. rubrum, the fungus responsible for onychomycosis commonly known as nail infection," said Dr. Behzad Khosrovi, senior vice president of product development at NovaBay. "Nail fungus is notoriously difficult to treat predominantly due to the inability of many topical antifungal drugs to penetrate the nail, a hurdle we were able to overcome due to the proprietary characteristics of our compounds."

The study "In Vitro Evaluation of Stable Derivatives of the Chlorotaurines( )on Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis" tested formulations of both N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-chloro-2,2-dimethyltaurine (NVC-612), both proprietary NovaBay compounds, which are stable derivatives of endogenous chlorotaurines that possess potent and rapid antimicrobial activity against a wide range of pathogens. The endogenous chlorotaurines play an important role in mammalian innate immunity to invading pathogens.

"Onychomycosis represents a significant market opportunity for any topical agent," said Ron Najafi,
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
2. Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets
3. Premature ejaculation spray enables men to last 6 times longer after penetration
4. Lumension Security Receives Frost & Sullivan 2008 Global Market Penetration Leadership Award
5. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
6. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
7. LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
8. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
9. 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
10. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
11. Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... Providence, Rhode Island (PRWEB) July 25, 2014 ... very pleased to announce that Dr. Kerri Luzzo, Lead ... Under Forty Award" for her professional accomplishments in fertility ... (PBM). , At the 10th Annual PBN Awards ... Newport, Rhode Island, 40 of the most highly regarded, ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- The human ... effects of dehydration, a new study finds. ... researchers in England have found that the brain compensates ... the blood. "This research has helped us understand ... to extreme exercise in extreme conditions," study first author ...
Breaking Medicine News(10 mins):Health News:Distractions Seem More Troublesome With Age 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2
... about three-quarters of whites, Hispanics, CDC says , THURSDAY, ... powers of breast-feeding aren,t reaching black American women as ... study from the U.S. Centers for Disease Control and ... more than 80 percent of Hispanic mothers attempt to ...
... tumors escape the body,s natural immune surveillance has recently been ... The study shows how tumors can create a tolerant microenviroment ... features of lymph nodes. The discovery, published in Science ... 2010, underscores the role of the lymphatic system in cancer ...
... ... About Malaria Prevention Aboard an Eco-Friendly Bus , ... Atlanta, GA (Vocus) March 25, 2010 -- The United Nations Foundation,s ... announced today the launch of its Nothing But Nets Buzz Tour. The campaign will take ...
... ... cell-based strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s ... San Francisco, CA ... motor symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ...
... 33 percent higher risk of death, study finds, , ... do much better, in terms of survival, if they ... need, new research suggests. , The study found that ... need help from others have a 33 percent increased ...
... at the Eastern Virginia Medical School Strelitz Diabetes Center ... of Defense (DoD) Peer Reviewed Medical Research Program to ... Type 1 diabetes. David Taylor-Fishwick, PhD, ... Cell, Molecular and Islet Biology Laboratory, leads the team ...
Cached Medicine News:Health News:Black Women Least Likely to Breast-Feed in U.S. 2Health News:Black Women Least Likely to Breast-Feed in U.S. 3Health News:Tumors hide out from the immune system by mimicking lymph nodes 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:Accepting Help Improves Survival Among Diabetics 2Health News:Accepting Help Improves Survival Among Diabetics 3Health News:EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes 2
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of a ... to a recent study, which shows how grief in pregnancy ... http://photos.prnewswire.com/prnh/20140723/129709 According to US News ... more likely than others to grow up overweight or obese, ... There were two specific types of stress that caused obesity: ...
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation, today announced that enrollment in the Phase ... (ACS) will continue based on the positive outcome of ... safety data. An independent statistician completed ...
... announced that it has secured an exclusive license for ... existing clinical work whereby a medicated tampon was used ... States patents. Joseph Fuisz, Managing Partner of ... acquisition, having had a long standing interest in vaginal ...
Cached Medicine Technology:Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 2Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 3Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: